Alphyn Receives Notice of Claims Allowance for U.S. Patent Covering Zabalafin Hydrogel

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Alphyn-USPTO-Hydrogel

More Like This

PR Newswire associated0

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024

PR Newswire associated0

Alphyn Doses First Patients in CLEAR-AD1 Global Phase 2b Clinical Trial Program for Atopic Dermatitis

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

SIFI announces allowance of patent on polihexanide for Europe and commercial launch of AKANTIOR® in Germany

CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Innovaderm, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

PR Newswire associated0

Amacathera Collaborates With Leading Global Pharmaceutical Company To Develop Single-Injection, Long-Acting Biologic Using Its Advanced Hydrogel Delivery Platform, Amacagel™

Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries